Nanobiotix S.A.

Nanobiotix S.A.

NNBXF

NNBXFNanobiotix S.A. US flag

Other OTC

9.10

USD

- -

- -

Return %

Stock

S&P500

1Y

- -

26.53

3Y

- -

76.60

5Y

- -

80.11

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Laurent Levy
Full Time Employees: 103
Sector: Healthcare
Industry: Biotechnology
Address: 60 rue de Wattignies Paris France 75012
IPO Date: Jan 21, 2020
Website: nanobiotix.com
Similar Companies: Xenon Pharmaceuticals Inc. (XENE)
Vectus Biosystems Limited (VBS.AX)
Innovent Biologics, Inc. (IVBXF)
Cingulate Inc. (CING)
Caladrius Biosciences, Inc. (CLBS)
Processa Pharmaceuticals, Inc. (PCSA)
Business: Nanobiotix S.A. (Ticker: NNBXF) is a late-stage clinical biotechnology company that pioneers the discovery, development, manufacture, and commercialization of disruptive physics-based nanotherapeutics, primarily focused on enhancing radiotherapy efficacy for cancer treatment; its proprietary NanoXray platform includes the lead product candidate NBTXR3 (also known as JNJ-1900), a first-in-class radioenhancer designed to selectively amplify radiation dose within tumor cells across solid tumors such as head and neck, lung, and others without increasing exposure to healthy tissues, thereby improving tumor destruction and priming immune responses against metastases; the company also advances preclinical research in cancer immunotherapies. Founded in 2003 as a spin-off from the State University of New York at Buffalo and headquartered at 60 Rue de Wattignies in Paris, France, Nanobiotix operates globally with a U.S. affiliate in Cambridge, Massachusetts, and maintains partnerships including a broad clinical research collaboration with The University of Texas MD Anderson Cancer Center since 2019, a licensing agreement with Lian Oncology Limited for NBTXR3 commercialization in Greater China, South Korea, Singapore, and Thailand, and a comprehensive global co-development and commercialization deal with Janssen Pharmaceutica NV, a Johnson & Johnson company, announced in 2023 that encompasses initial focus on head and neck cancers with expansion potential up to $2.6 billion in milestones. In late 2025, Nanobiotix secured a strategic non-dilutive royalty monetization agreement with HealthCare Royalty for up to $71 million—an upfront $50 million plus $21 million contingent—extending cash runway into early 2028 to support ongoing Phase 3 trials in head and neck cancer, lung cancer development, and next-generation nanotherapeutic platforms; the company also closed an additional $4.8 million investment from Johnson & Johnson Innovation – JJDC in December 2023, bolstering its path toward self-sustainability amid key clinical milestones.

Company News